Julie Scallen is a partner in the Boston office of Latham & Watkins and serves as Corporate Department Chair for the Boston office. She focuses her practice on mergers and acquisitions and private equity transactions. Ms. Scallen represents public and private companies and private equity funds in acquisitions, leveraged buyouts, dispositions, private equity and venture capital financings, strategic alliances, joint ventures, and licensing transactions.
Prior to joining Latham, Ms. Scallen practiced at another leading law firm.
Ms. Scallen’s recent transactions include representing:
- AMAG Pharmaceuticals, Inc. in its US$1.025 billion reverse merger with Lumara Health, a specialty pharmaceutical company
- Atrium Medical Corporation, a healthcare manufacturer of medical device technologies, in its US$680 million acquisition by Getinge AB
- Boston Scientific Corporation in its US$300 million acquisition of Apama Medical, Inc., a developer of radio-frequency balloon catheters
- Boston Scientific Corporation in its US$435 million acquisition of Symetis SA, a Swiss structural heart company
- Boston Scientific Corporation in its US$210 acquisition of EndoChoice Holdings, Inc., a developer of devices for gastrointestinal conditions
- Boston Scientific Corporation in its equity investment in, and sales and marketing alliance with, Preventice Solutions, a developer of mobile health solutions
- Boston Scientific Corporation in its US$415 million acquisition of the Interventional Division of Bayer AG, a global pharmaceutical and chemical company
- Boston Scientific Corporation in its acquisition of StarMedTec GmbH, a German medical laser systems company
- Boston Scientific Corporation in its US$275 million acquisition of the Electrophysiology Division of C.R. Bard, a company engaged in the provision of devices for the diagnosis and treatment of cardiac arrhythmias
- Boston Scientific Corporation in its US$1.35 billion acquisition of Cameron Health, Inc., a company that develops implantable cardioverter defibrillators
- Boston Scientific Corporation in its US$425 million acquisition of Vessix Vascular, Inc., a developer of a renal denervation system
- Claros Diagnostics, Inc., a developer of a microfluidics-based test system, in its US$49 million sale to Opko Health, Inc.
- Cimpress N.V., in its €91 million acquisition of Exagroup SAS, a French web-to-print company
- Micronetics, Inc., a manufacturer of microwave and radio frequency components, in its US$75 million sale to Mercury Computer Systems, Inc.